# TABLES OF CONTENTS

<table>
<thead>
<tr>
<th>CHAPTER NO.</th>
<th>TITLE</th>
<th>PAGE NO.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ABSTRACT</td>
<td>vi</td>
</tr>
<tr>
<td></td>
<td>LIST OF TABLES</td>
<td>xvi</td>
</tr>
<tr>
<td></td>
<td>LIST OF FIGURES</td>
<td>xvii</td>
</tr>
<tr>
<td></td>
<td>LIST OF SYMBOLS AND ABBREVIATIONS</td>
<td>xx</td>
</tr>
<tr>
<td>1</td>
<td>INTRODUCTION</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>1.1 Pharmacodynamic Interactions</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>1.2 Pharmacokinetic Interactions</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>1.3 Herbal Constituents are Substrates for Drug Metabolizing Enzymes</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>1.4 CYP450 Mediated Pharmacokinetic Herb-Drug Interactions</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>1.4.1 Inhibition of CYP450</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>1.4.2 Induction of CYP450</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>1.5 Clinical Significance of Identification of Drugs that may Interact with Herbs</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>1.6 Approaches to Identifying Drugs that may Interact with Herbal Medicines</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td>1.7 Predicting Drug’s Potential for Interaction with Herbal Medicines</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>1.8 Problem Statement</td>
<td>16</td>
</tr>
</tbody>
</table>
1.9 Information about MenoAct450 Polyherbal Formulation

1.9.1 Rationality of the Combination of Herbal Extracts in the Formulation

1.9.2 Targets of selected herbal extracts

1.10 Hypothesis of the Study

2 REVIEW OF LITERATURE

3 SCOPE AND OBJECTIVES

4 QUANTIFICATION OF SELECTED BIOMARKERS IN THE HERBAL EXTRACT AND FORMULATION

4.1 INTRODUCTION

4.2 MATERIALS AND METHODS

4.2.1 Plant Extracts and Investigational formulation (MenoAct450)

4.2.2 Chemicals

4.2.3 Sample Preparation

4.2.4 Capsule Extraction Method

4.2.5 Standard Preparation

4.2.6 Standardization of plant extracts by RP-HPLC

4.2.7 Chromatographic Conditions

4.2.8 Method Validation

4.2.8.1 Selectivity and specificity
4.2.8.2 Calibration 38

4.2.8.3 Limit of Detection (LOD) and Limit of Quantitation (LOQ) 39

4.2.8.4 Repeatability and intermediate precision 39

4.2.8.5 Accuracy and Precision 40

4.2.8.6 Robustness 40

4.3 RESULTS AND DISCUSSION 41

4.3.1 Optimization of HPLC Chromatographic Conditions for β-Sitosterol and Stigmasterol Quantification 41

4.3.2 Optimization of HPLC Chromatographic Conditions for Gallic acid and Ellagic acid Quantification 42

4.3.3 Quantification of Bioactive Compounds 43

4.3.4 Method Validation for HPLC Quantification 43

5 CYP450 INHIBITION ASSAY USING POOLED RAT LIVER MICROSONMES 49

5.1 INTRODUCTION 49

5.2 MATERIALS AND METHODS 52

5.2.1 Preparation of Rat Liver Microsomes 52
5.2.2 Determination of Protein Content in the Pooled Rat Liver Microsomes

5.2.3 CYP450-Carbon Monoxide (CO) Complex Assay

5.3 RESULTS AND DISCUSSION

5.3.1 Determination of CYP450 Concentration

5.3.2 Percentage Inhibition through CYP450-CO Complex Assay

6 HIGH THROUGHPUT FLUOROMETRIC ASSAY WITH CYP3A4 AND CYP2D6

6.1 INTRODUCTION

6.1.1 Assessment of CYP inhibition in vitro

6.1.2 Generating in vitro inhibition data

6.1.3 High Throughput Fluorometric Assay

6.2 MATERIALS AND METHODS

6.2.1 Chemicals

6.2.2 Preparation of Standard Curve

6.2.3 High Throughput Fluorometric Assay Method

6.2.4 Preparation and dispensing of Master Pre-Mix

6.3 RESULTS AND DISCUSSION

7 IN SILICO STUDIES OF SELECTED BIOMARKERS AND CONTROLS WITHIN
CYP3A4 AND CYP2D6 MOLECULE ACTIVE SITE

7.1 INTRODUCTION 74

7.2 MATERIALS AND METHODS 77

7.2.1 Dataset for analysis 77

7.2.2 Ligand preparation for molecular docking 77

7.2.3 Protein preparation for molecular docking 78

7.2.4 Molecular docking protocol 79

7.3 RESULTS AND DISCUSSION 82

7.3.1 Overall performance in binding mode reproduction 82

7.3.2 Docking Studies of Active Constituents, Ketoconazole and Quinidine within CYP3A4 and CYP2D6 Molecule Active Site 84

8 A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED DRUG INTERACTION STUDY OF MENOACT450 IN HEALTHY, ADULT, FEMALE, HUMAN SUBJECTS 86

8.1 INTRODUCTION 86

8.2 MATERIALS AND METHODS 89

8.2.1 Study protocol 89

8.2.2 Study Participants 89